# Data Sheet (Cat.No.T4235)



## Roblitinib

## **Chemical Properties**


CAS No.: 1708971-55-4

Formula: C25H30N8O4

Molecular Weight: 506.56

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



# **Biological Description**

Description	Roblitinib (FGF-401) is an inhibitor of human fibroblast growth factor receptor 4 (FGFR4) with potential antineoplastic activity. Upon administration, Roblitinib binds to and inhibits FGFR4, leading to the inhibition of tumor cell proliferation in FGFR4-overexpressing cells. It is a receptor tyrosine kinase upregulated in certain tumor cells and involved in proliferation, differentiation, angiogenesis, and survival.
Targets(IC50)	FGFR
In vivo	FGF-401 is a FGFR4 inhibitor developed for the treatment of solid tumor. FGF-401 is a FGFR4 inhibitor in phase I/II Clinicalal studies for the treatment of positive FGFR4 and KLB expresion solid tumors and hepatocellular carcinoma

#### **Solubility Information**

Solubility	DMSO: Slightly soluble,
	(< 1 mg/ml refers to the product slightly soluble or insoluble)

# **Preparing Stock Solutions**

	1mg	5mg	10mg
1 mM	1.9741 mL	9.8705 mL	19.741 mL
5 mM	0.3948 mL	1.9741 mL	3.9482 mL
10 mM	0.1974 mL	0.987 mL	1.9741 mL
50 mM	0.0395 mL	0.1974 mL	0.3948 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

#### Reference

#### WO2015059668A1

Tao Z, Cui Y, Xu X, et al. FGFR redundancy limits the efficacy of FGFR4-selective inhibitors in hepatocellular carcinoma. Proceedings of the National Academy of Sciences. 2022, 119(40): e2208844119.

Page 1 of 2 www.targetmol.com

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:36 Washington Street,Wellesley Hills,MA 02481

Page 2 of 2 www.targetmol.com